Vadodara-Based Company Raises Rs 100 Crore from 10 Anchor Investors Ahead of IPO; Check Details

Multispecialty hospital chain Gujarat Kidney and Super Speciality has raised Rs 100.01 crore from 10 anchor investors on December 19. The company’s IPO is scheduled to open for public subscription on December 22. It has allotted 87.73 lakh equity shares to anchor investors at the upper end of the price band.

The Gujarat-based hospital chain plans to raise Rs 250.8 crore through its initial public offering, comprising a fresh issue of 2.2 crore equity shares priced in the range of Rs 108–Rs 114 per share. The IPO will be open to the public from December 22.

Craft Emerging Market Fund, through its two sub-funds—Citadel Capital Fund and Elite Capital Fund—emerged as the largest anchor investor, acquiring 39.47 lakh shares worth Rs 45 crore. This was followed by Khandelwal Finance, which invested Rs 15 crore for 13.16 lakh shares, and Venus Investments, which purchased 8.77 lakh shares for Rs 10 crore. Other anchor investors included Nexus Global Opportunities Fund, Arnesta Global Opportunities Fund, Zeta Global Funds, Religo Commodities Ventures Trust, Sunrise Investment Trust, and Innovative Vision Fund, each investing Rs 5 crore by acquiring 4.38 lakh shares.

Vadodara-based Gujarat Kidney and Super Speciality Limited is a multispecialty healthcare provider with operations across multiple locations in Gujarat. The company is launching its IPO on the NSE and BSE mainboard to fund several objectives, including the proposed acquisition of Parekhs Hospital in Ahmedabad, partial payment for the already acquired Ashwini Medical Center, capital expenditure for setting up a new hospital in Vadodara, purchase of robotic equipment, repayment or prepayment of certain secured borrowings, funding inorganic growth through unidentified acquisitions, general corporate purposes, and increasing its stake in its Bharuch-based subsidiary, Harmony Medicare Private Limited. Details of the company’s operations have been sourced from its prospectus by the Business Remedies team.

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited (GKSL) focuses on delivering multispecialty healthcare services across Gujarat. The company currently operates seven multispecialty hospitals and four pharmacies. It has a total bed capacity of 490 beds, with 455 beds approved and 340 beds operational.

The hospital network includes Gujarat Kidney and Super Speciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Pamland Hospital Private Limited (Bharuch), Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), and Ashwini Medical Center (Anand). The company also runs Ashwini Medical Store in Anand.

Gujarat Super Speciality Hospital offers medical services across multiple disciplines, including internal medicine, general surgery, minimally invasive surgery, orthopaedics and trauma care, joint replacement, obstetrics and gynaecology, respiratory care, non-interventional cardiology, diabetology, and anaesthesiology. As of June 30, 2025, the company employed 89 doctors, 332 nurses, and 338 other staff members.

On the financial front, the company reported total revenue of Rs 5.48 crore and a profit after Tax of Rs 1.71 crore in FY24. In FY25, revenue rose sharply to Rs 40.40 crore, while profit after tax increased to Rs 9.50 crore. For the quarter ended June 30, 2025 (FY26), the company recorded revenue of Rs 15.27 crore and a profit after tax of Rs 5.40 crore, translating into a strong PAT margin of 35.41 percent.

The IPO of Gujarat Kidney and Super Speciality Limited will open on December 22, 2025, and close on December 24, 2025. The issue comprises up to 2,20,00,000 equity shares of face value Rs 2 each and will be listed on the NSE and BSE mainboard. The issue is being managed by Nirbhay Capital Services Private Limited, the book-running lead manager.

Disclaimer: The article is for informational purposes only and not investment advice.